

15-2

2740-871 1

The Practice of Medicinal Chemistry

Edited by

CAMILLE G. WERMUTH

*Laboratoire de Pharmacochimie Moléculaire, Faculté de Pharmacie,
Université Louis Pasteur, Illkirch, France*



ACADEMIC PRESS

Harcourt Brace and Company, Publishers

London San Diego New York

Boston Sydney Tokyo Toronto

Contents

Contributors	ix
Foreword	xiii
Preface	xv
Part I: General Aspects of Medicinal Chemistry	
1 Medicinal chemistry: Definition and objectives. Drug and disease classifications <i>Camille G. Wermuth</i>	3
2 Discovering new drugs: the legacy of the past, present approaches, and hopes for the future <i>Philippe Meyer</i>	11
3 Measurement and expression of drug effects <i>Jean-Paul Kan</i>	25
4 The three main phases of drug activity: the pharmaceutical, the pharmacokinetic and the pharmacodynamic phases <i>Camille G. Wermuth</i>	41
Part II: Drug Targets and Lead Compound Discovery Strategies	
5 Drug targets—molecular mechanisms of drug action <i>Jean-Pierre Gies</i>	55
6 Strategies in the search for new lead compounds or original working hypotheses <i>Camille G. Wermuth</i>	81

7	Natural products as pharmaceuticals and sources for lead structures <i>David G.I. Kingston</i>	101
8	Combinatorial libraries and high-throughput synthesis <i>Sheila Hobbs de Witt</i>	117
9	Synthesis of peptide libraries for lead structure screening <i>Victor J. Hruby</i>	135
10	The contribution of molecular biology to drug discovery <i>Adrian N. Hobden</i>	153
11	Electronic screening: Lead finding from database mining <i>Hans-Peter Weber</i>	167

Part III: Primary Exploration of Structure–Activity Relationships

12	Molecular variations in homologous series: Vinylogues and benzologues <i>Camille G. Wermuth</i>	181
13	Molecular variations based on isosteric replacements <i>Camille G. Wermuth</i>	203
14	Ring transformations <i>Camille G. Wermuth</i>	239
15	Identical and nonidentical twin drugs <i>Jean-Jacques Bourguignon</i>	261
16	Application strategies for primary structure–activity relationship exploration <i>Camille G. Wermuth</i>	295

Part IV: Substituents and Functions: Qualitative and Quantitative Aspects of Structure–Activity Relationships

17	Specific substituent effects <i>Camille G. Wermuth</i>	311
18	The role of functional groups in drug–receptor interactions <i>Peter R. Andrews</i>	345
19	Quantitative approaches to structure–activity relationships <i>Han van de Waterbeemd</i>	367

Part V: Spatial Organization, Receptor Mapping and Molecular Modelling

20	Stereochemical aspects of drug action I: Conformational restriction, steric hindrance and hydrophobic collapse <i>Phillip A. Hart and Daniel H. Rich</i>	393
21	Stereochemical aspects of drug action II: Optical isomerism <i>Miklós Simonyi and Gábor Maksay</i>	413

- 22 Pharmacophore identification and receptor mapping 437
Hans-Dieter Höltje
- 23 Three-dimensional quantitative structure–activity relationships: D₂ dopamine agonists as an example 459
Yvonne Connolly Martin and C. Thomas Lin
- 24 The use of X-ray structures of receptors and enzymes in drug discovery 485
Jean-Michel Rondeau and Herman Schreuder
- 25 Protein homology modelling and drug discovery 523
Marcel F. Hibert
- 26 The transition from agonist to antagonist activity: Symmetry and other considerations 547
David J. Triggle
- 27 Design of peptidomimetics 571
Hiroshi Nakanishi and Michael Kahn

Part VI: Chemical Modifications Influencing the Pharmacokinetic Properties

- 28 The fate of xenobiotics in living organisms 593
Frans M. Belpaire and Marc G. Bogaert
- 29 Biotransformation reactions 615
Camille G. Wermuth and Bernard Testa
- 30 Chemical aspects of biotransformations leading to toxic metabolites 643
André Picot and Anne-Christine Macherey
- 31 Designing prodrugs and bioprecursors I: Carrier prodrugs 671
Camille G. Wermuth, Jean-Cyr Gaignault and Christian Marchandea
- 32 Designing prodrugs and bioprecursors II: Bioprecursor prodrugs 697
Camille G. Wermuth
- 33 Macromolecular carriers for drug targeting 717
Etienne H. Schacht, Stefan Vansteenkiste and Len Seymour

Part VII: Pharmaceutical and Chemical Formulation Problems

- 34 Preparation of water-soluble compounds through salt formation 739
Bradley D. Anderson and Karl P. Flora
- 35 Preparation of water-soluble compounds by covalent attachment of solubilizing moieties 755
Camille G. Wermuth
- 36 Drug solubilization with organic solvents, or using micellar solutions or other colloidal dispersed systems 777
Kurt H. Bauer
- 37 Improvement of drug properties by cyclodextrins 793
Kaneto Uekama and Fumitoshi Hirayama

38	Chemical and physicochemical solutions to formulation problems <i>Camille G. Wermuth</i>	827
----	---	-----

Part VIII: Development of New Drugs: Legal and Economic Aspects

39	From discovery to market availability <i>Jacques A. Dangoumau</i>	847
----	--	-----

40	Drug nomenclature <i>Sabine Kopp-Kubel</i>	863
----	---	-----

41	Legal aspects of product protection – what a medicinal chemist should know about patent protection <i>Maria Souleau</i>	879
----	---	-----

42	The consumption and production of pharmaceuticals <i>Bryan G. Reuben</i>	903
----	---	-----

	Index	939
--	--------------	-----

A colour plate section can be found between pages 446 and 447.